Angiotensin-II receptor antibody - Materia Medica HoldingAlternative Names: Cardosten
Latest Information Update: 16 Sep 2011
At a glance
- Originator Materia Medica Holding Research and Production Company
- Class Antibodies; Heart failure therapies
- Mechanism of Action Angiotensin type 1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Clinical Phase Unknown Heart failure